Physician profile
Ashraf Hamza
NPI 1407137375
$5,230.44
in general payments reported to CMS, 2019-2025
12 companies · $212 in 2025
The $212 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $122 · 2021: $481 · 2022: $99.91 · 2023: $3,371 · 2024: $466 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,500 · Food and Beverage: $1,454 · Travel and Lodging: $1,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,500.00 |
| Food and Beverage | $1,454.13 |
| Travel and Lodging | $1,094.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $2,990.49 | 2021-2023 | Monoferric |
| Daiichi Sankyo INC. | $704.09 | 2019-2024 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $330.30 | 2023-2025 | Libtayo |
| Axsome Therapeutics, INC. | $228.89 | 2024-2025 | Auvelity |
| Amgen INC. | $218.10 | 2019-2023 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $151.20 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $123.06 | 2024 | Rexulti |
| Alkermes, INC. | $119.98 | 2023 | Lybalvi |
| Novo Nordisk INC | $119.88 | 2019 | |
| Sobi, INC | $117.18 | 2023 | |
| Amag Pharmaceuticals, INC. | $107.84 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $19.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Hamza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.